Monitor for immediate selling by insiders (Ting Yang, Lina Deng, David Lazar) which could pressure the stock. The company's lack of pipeline and going-concern status make further dilutive financing or a distressed sale likely. Traders should watch for any 8-K filings regarding strategic alternatives or additional capital raises.
Price Chart
Executive Summary
Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David Lazar) to resell up to 18,864,000 shares of common stock, representing approximately 14.2% of outstanding shares. The company will not receive any proceeds. This filing comes amid a severe operational crisis: the company has discontinued all clinical development of its lead candidate Decoy20, has no active programs, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The resale registration creates significant overhang and facilitates insider selling, compounding the fundamental distress.
Key Facts
- 18,864,000 shares registered for resale by three selling stockholders (Ting Yang, Lina Deng, David Lazar) — approximately 14.2% of the 133,242,324 shares outstanding.
- Company receives no proceeds; all proceeds go to selling stockholders.
- Decoy20 clinical programs fully discontinued; no active clinical development programs.
- Auditor's report includes a going-concern explanatory paragraph.
- Change of control occurred in March 2026; new management and board in place.
- Multiple dilutive financings in the past 18 months: June 2026 private placement ($12M), June 2025 private placement ($2.3M convertible notes), and various other offerings.
Financial Impact
Potential overhang of ~14.2% of outstanding shares; at the June 22, 2026 closing price of $3.775, the registered shares have a market value of approximately $71.2 million.
Risk Factors
- Insider selling from the registered shares could create sustained downward pressure.
- Company may need to raise additional capital at distressed terms, further diluting existing shareholders.
- Inability to secure a strategic transaction or financing could lead to delisting or bankruptcy.
- Concentrated ownership (96.2% held by a small group after March 2026 transfer) creates governance and liquidity risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-030346 |
| Exhibit: ex107.htm | 0001493152-26-030346 |
| Exhibit: ex5-1.htm | 0001493152-26-030346 |
| Exhibit: ex23-2.htm | 0001493152-26-030346 |
| Document: 0001493152-26-030346-index-headers.html | 0001493152-26-030346 |
| Document: 0001493152-26-030346-index.html | 0001493152-26-030346 |
| Document: 0001493152-26-030346.txt | 0001493152-26-030346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access